- Home
- BEAM vs VKTX Comparison
BEAM vs VKTX Comparison
Compare BEAM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BEAM | VKTX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BEAM | VKTX |
|---|---|---|
| Price | $32.25 | $29.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $50.75 | ★ $95.86 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $22.96 |
| 52 Week High | $36.44 | $43.15 |
Technical Indicators
Market Signals| Indicator | BEAM | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 43.42 |
| Support Level | $26.23 | $29.32 |
| Resistance Level | $34.29 | $36.77 |
| Average True Range (ATR) | 1.88 | 1.21 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 78.28 | 33.60 |
Price Performance
Historical ComparisonAbout BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.